K. George Chandy

Department of Physiology and Biophysics, University of California, Irvine (UCI)

Affiliated withUniversity of California, Irvine (UCI)Nanyang Technological University

Research Area

Biography

K. George Chandy has not added Biography.
If you are K. George Chandy and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 12	Year
Publication title Cited by 19	2007
Publication title Cited by 27	2007
Publication title Cited by 18	2007
Publication title Cited by 87	2007
Publication title Cited by 36	2007

Other Publications

Article	Year
Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. The Journal of biological chemistry\| PubMed ID: 11724775	2002
Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I ... European journal of human genetics : EJHG\| PubMed ID: 11896454	2002
Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3. Biochemistry\| PubMed ID: 12356296	2002
A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. The Journal of biological chemistry\| PubMed ID: 12511563	2003
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. The Journal of clinical investigation\| PubMed ID: 12782673	2003
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation\| PubMed ID: 12939222	2003
Potassium channels as therapeutic targets for autoimmune disorders. Current opinion in drug discovery & development\| PubMed ID: 14579513	2003
SK3-1C, a dominant-negative suppressor of SKCa and IKCa channels. The Journal of biological chemistry\| PubMed ID: 14638680	2004
International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacological reviews\| PubMed ID: 14657415	2003
Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. The Journal of clinical investigation\| PubMed ID: 14966567	2004
SKCa channels mediate the medium but not the slow calcium-activated afterhyperpolarization in cortical neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience\| PubMed ID: 15071101	2004
K+ channels as targets for specific immunomodulation. Trends in pharmacological sciences\| PubMed ID: 15120495	2004
Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Molecular pharmacology\| PubMed ID: 15155830	2004
K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 15240664	2004
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Molecular pharmacology\| PubMed ID: 15665253	2005
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 16043714	2005
Potassium channels, memory T cells, and multiple sclerosis. The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry\| PubMed ID: 16282596	2005
International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacological reviews\| PubMed ID: 16382103	2005
International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacological reviews\| PubMed ID: 16382104	2005
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 17088564	2006
The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation. The Journal of biological chemistry\| PubMed ID: 17984097	2008
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. The Journal of clinical investigation\| PubMed ID: 18688283	2008
Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity\| PubMed ID: 18835197	2008
Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. Expert opinion on therapeutic targets\| PubMed ID: 19538097	2009
The functional network of ion channels in T lymphocytes. Immunological reviews\| PubMed ID: 19754890	2009
Potassium channel modulation by a toxin domain in matrix metalloprotease 23. The Journal of biological chemistry\| PubMed ID: 19965868	2010
Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nature communications\| PubMed ID: 21629267	2011
18F-Fallypride PET of pancreatic islets: in vitro and in vivo rodent studies. Journal of nuclear medicine : official publication, Society of Nuclear Medicine\| PubMed ID: 21680697	2011
Therapeutic potential of peptide toxins that target ion channels. Inflammation & allergy drug targets\| PubMed ID: 21745182	2011
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon : official journal of the International Society on Toxinology\| PubMed ID: 21867724	2011
Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells. EMBO molecular medicine\| PubMed ID: 22496117	2012
Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 22581856	2012
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 22637724	2012
Modulation of voltage-gated K+ channels by the sodium channel β1 subunit. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 23090990	2012
Intracellular trafficking of the KV1.3 potassium channel is regulated by the prodomain of a matrix metalloprotease. The Journal of biological chemistry\| PubMed ID: 23300077	2013
Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 23729813	2013
Shaker-related potassium channels in the central medial nucleus of the thalamus are important molecular targets for arousal suppression by volatile general anesthetics. The Journal of neuroscience : the official journal of the Society for Neuroscience\| PubMed ID: 24107962	2013
Blockade of Kv1.3 channels ameliorates radiation-induced brain injury. Neuro-oncology\| PubMed ID: 24305723	2014
Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB journal : official publication of the Federation of American Societies for Experimental Biology\| PubMed ID: 24891519	2014
Immunology: Channelling potassium to fight cancer. Nature\| PubMed ID: 27626384	2016
International Union of Basic and Clinical Pharmacology. C. Nomenclature and Properties of Calcium-Activated and Sodium-Activated Potassium Channels. Pharmacological reviews\| PubMed ID: 28267675	2017
Tissue resident memory T cells in the human conjunctiva and immune signatures in human dry eye disease. Scientific reports\| PubMed ID: 28345628	2017
Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease. Current opinion in chemical biology\| PubMed ID: 28412597	2017